112 related articles for article (PubMed ID: 21054401)
1. Involvement of YC-1 in extracellular signal-regulated kinase action in rat cremasteric muscle.
Hsieh YH; Huang SS; Day YJ; Wei FC; Hung LM
J Pharm Pharmacol; 2010 Dec; 62(12):1746-52. PubMed ID: 21054401
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells.
Bellamy TC; Garthwaite J
Br J Pharmacol; 2002 May; 136(1):95-103. PubMed ID: 11976273
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
[TBL] [Abstract][Full Text] [Related]
5. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
[TBL] [Abstract][Full Text] [Related]
6. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
7. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide.
Hoenicka M; Becker EM; Apeler H; Sirichoke T; Schröder H; Gerzer R; Stasch JP
J Mol Med (Berl); 1999 Jan; 77(1):14-23. PubMed ID: 9930922
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1.
Martin NI; Derbyshire ER; Marletta MA
Bioorg Med Chem Lett; 2007 Sep; 17(17):4938-41. PubMed ID: 17587571
[TBL] [Abstract][Full Text] [Related]
9. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.
Wohlfart P; Malinski T; Ruetten H; Schindler U; Linz W; Schoenafinger K; Strobel H; Wiemer G
Br J Pharmacol; 1999 Nov; 128(6):1316-22. PubMed ID: 10578147
[TBL] [Abstract][Full Text] [Related]
10. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Stasch JP; Hobbs AJ
Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
[TBL] [Abstract][Full Text] [Related]
11. An evolutionarily conserved mechanism for sensitization of soluble guanylyl cyclase reveals extensive nitric oxide-mediated upregulation of cyclic GMP in insect brain.
Ott SR; Delago A; Elphick MR
Eur J Neurosci; 2004 Sep; 20(5):1231-44. PubMed ID: 15341595
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway.
Hwang TL; Wu CC; Guh JH; Teng CM
Biochem Pharmacol; 2003 Jul; 66(1):149-56. PubMed ID: 12818375
[TBL] [Abstract][Full Text] [Related]
13. The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells.
Ramos-Espiritu LS; Hess KC; Buck J; Levin LR
J Pharmacol Exp Ther; 2011 Sep; 338(3):925-31. PubMed ID: 21665942
[TBL] [Abstract][Full Text] [Related]
14. Kappa-opioid receptor agonist protects the microcirculation of skeletal muscle from ischemia reperfusion injury.
Lin JY; Hung LM; Lai LY; Wei FC
Ann Plast Surg; 2008 Sep; 61(3):330-6. PubMed ID: 18724138
[TBL] [Abstract][Full Text] [Related]
15. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.
Nakane M; Hsieh G; Miller LN; Chang R; Terranova MA; Moreland RB; Kolasa T; Brioni JD
Int J Impot Res; 2002 Apr; 14(2):121-7. PubMed ID: 11979328
[TBL] [Abstract][Full Text] [Related]
16. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 receptors via Gbetagamma-dependent activation of c-Src kinase.
Murthy KS
J Pharmacol Exp Ther; 2008 Apr; 325(1):183-9. PubMed ID: 18180373
[TBL] [Abstract][Full Text] [Related]
18. Ischemic preconditioning ameliorates microcirculatory disturbance through downregulation of TNF-alpha production in a rat cremaster muscle model.
Hung LM; Wei W; Hsueh YJ; Chu WK; Wei FC
J Biomed Sci; 2004; 11(6):773-80. PubMed ID: 15591774
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of carbon monoxide-induced relaxation of rat aorta by YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole].
McLaughlin BE; Chretien ML; Choi C; Brien JF; Nakatsu K; Marks GS
Can J Physiol Pharmacol; 2000 Apr; 78(4):343-9. PubMed ID: 10772062
[TBL] [Abstract][Full Text] [Related]
20. YC-1, a potent antithrombotic agent, induces lipolysis through the PKA pathway in rat visceral fat cells.
Chin CH; Tsai FC; Chen SP; Wang KC; Chang CC; Pai MH; Fong TH
Eur J Pharmacol; 2012 Aug; 689(1-3):1-7. PubMed ID: 22659114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
